Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tilo Andus

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The American Journal of Gastroenterology|October 19, 2002
Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's diseaseHans Herfarth, Florian Obermeier, Tilo Andus, et al.
The American Journal of Gastroenterology|July 4, 2002
Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's diseaseCornelia M Gelbmann, Gerhard Rogler, Volker Gross, et al.
Zeitschrift Fur Gastroenterologie|August 16, 2023
[Use of specific antidotes in DOAC-associated severe gastrointestinal bleeding - an expert consensus - Antagonozation of direct oral anticoagulants in gastrointestinal hemorrhages]Valentin Fuhrmann, Jürgen Koscielny, Thomas Vasilakis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 14, 2005
Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trialEugen Musch, Tilo Andus, Wolfgang Kruis, et al.
Pharmacogenetics|October 3, 2002
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trialsSilvia Mascheretti, Jochen Hampe, Peter J P Croucher, et al.
Inflammatory Bowel Diseases|March 24, 2010
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitisTilo Andus, Andreas Kocjan, Moritz Müser, et al.
The Journal of Biological Chemistry|January 1, 2004
Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cellsStephan Kiessling, Gerhard Muller-Newen, Sandra N Leeb, et al.
Zeitschrift Fur Gastroenterologie|December 12, 2019
Markus Moehler, Salah-Edin Al-Batran, Tilo Andus, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The American Journal of Gastroenterology|October 19, 2002
Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's diseaseHans Herfarth, Florian Obermeier, Tilo Andus, et al.
The American Journal of Gastroenterology|July 4, 2002
Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's diseaseCornelia M Gelbmann, Gerhard Rogler, Volker Gross, et al.
Zeitschrift Fur Gastroenterologie|August 16, 2023
[Use of specific antidotes in DOAC-associated severe gastrointestinal bleeding - an expert consensus - Antagonozation of direct oral anticoagulants in gastrointestinal hemorrhages]Valentin Fuhrmann, Jürgen Koscielny, Thomas Vasilakis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 14, 2005
Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trialEugen Musch, Tilo Andus, Wolfgang Kruis, et al.
Pharmacogenetics|October 3, 2002
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trialsSilvia Mascheretti, Jochen Hampe, Peter J P Croucher, et al.
Inflammatory Bowel Diseases|March 24, 2010
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitisTilo Andus, Andreas Kocjan, Moritz Müser, et al.
The Journal of Biological Chemistry|January 1, 2004
Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cellsStephan Kiessling, Gerhard Muller-Newen, Sandra N Leeb, et al.
Zeitschrift Fur Gastroenterologie|December 12, 2019
Markus Moehler, Salah-Edin Al-Batran, Tilo Andus, et al.
Pageof 2